ClinicalTrials.gg
RecruitingNCT06337838BRACKETSUpdated May 22, 2026

Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial

A Phase 3 interventional study of Desmopressin Injectable Solution and Tranexamic Acid Injectable Product in Chronic Kidney Diseases, Acute Kidney Injury and Bleeding, sponsored by Hamilton Health Sciences Corporation. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Hamilton Health Sciences Corporation · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 215 studies in Renal Insufficiency, Chronic with a site in Canada — 37 open to participants now, 61 under way, 16 of them phase 3. Renal Insufficiency, Chronic · Canada.

Planned enrollment
112th of 173
100 · median 195
Started
2025
with 13 others
Phase 3
59 of 215
8 open now
Primary completion
2027-02
later than 30 of 60 live
Registered
174th of 215
by date

Among the 215 studies in Renal Insufficiency, Chronic with a site in Canada, this one is the 112th largest by planned enrollment of the 173 interventional ones that give a count, is one of 14 that started in 2025, is one of 59 in phase 3, reaches primary completion later than 30 of the 60 other live ones, and was the 174th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

37 of the 215 studies in Renal Insufficiency, Chronic with a site in Canada are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 215 studies in Renal Insufficiency, Chronic with a site in Canada, or all of them as a file.
02

Study summary

The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.

Read the detailed description

Perioperative administration of TXA reduces bleeding risk in surgical patients. However, large clinical trials have excluded patients with advanced kidney disease, so the benefits remain uncertain in this population, and there is potential for harm. The benefit of desmopressin, which is purported to more directly address the defect of primary hemostasis believed important in severe kidney disease more directly than TXA, has not been examined in adequate randomized control trials (RCTs). Both medications are generic and have been available for many years. To convincingly test these medications in patients with severe kidney disease, large, global trials are required. This pilot-phase trial will 1) inform the feasibility and design of a large international trial to evaluate the efficacy and safety of TXA and desmopressin in patients with advanced kidney disease undergoing noncardiac surgery, 2) provide preliminary data regarding the efficacy and safety of TXA and desmopressin in people with advanced kidney disease having noncardiac surgery, and 3) provide pharmacokinetic data to inform dose selection.

03

Conditions studied

  • Chronic Kidney Diseases
  • Acute Kidney Injury
  • Bleeding
  • Surgery

Keywords

  • Major Noncardiac Surgery
  • Tranexamic Acid
  • Desmopressin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Eligibility criteria specific to the tranexamic acid (TXA) factorial component of trial Inclusion Criteria:

  1. One of either:

    1.1. \<25 ml/min/1.73m2 estimated using the CKD-Epi 2009 or 2021creatinine-based equation from the most recent serum creatinine measurement done in the previous 6 months; or 1.2. Receipt of dialysis (including hemodialysis, peritoneal dialysis, hemofiltration, or hemodiafiltration) within the last 7 days;

  2. Planned noncardiac surgery (elective, urgent, or emergency surgery);
  3. Expected to require at least an overnight hospital admission after surgery;
  4. Age ≥18 years; and
  5. is obtained to participate in the BRACKETS-Pilot Trial.

Exclusion Criteria:

  1. Undergoing cardiac surgery;
  2. Undergoing intracranial neurosurgery;
  3. Undergoing surgery for creation or revision of arteriovenous fistula or graft for dialysis access;
  4. Planned use of prophylactic systemic TXA or ϵ-aminocaproic acid;
  5. or known allergy to TXA;
  6. History of seizure disorder;
  7. Recent (within 90 days) stroke, myocardial infarction, acute arterial thrombosis, deep venous thrombosis, pulmonary embolism, or thrombosis of an arteriovenous fistula or graft;
  8. History of thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome, or antiphospholipid antibody syndrome;
  9. Women who are known to be pregnant, breastfeeding, or who meet both of the following criteria: i) are of and do not have a negative pregnancy test documented in the 7 days before surgery, AND ii) are not using effective ; or
  10. Previously enrolled in the BRACKETS-Pilot Trial.

Eligibility criteria specific to the desmopressin factorial component of trial

Inclusion criteria:

1. Included in the TXA factorial.

Exclusion criteria:

  1. The hospital does not have access to desmopressin;
  2. Planned use of prophylactic desmopressin;
  3. Most recent serum sodium concentration \< 130 mEq/L;
  4. Known or suspected von Willebrand disease (any kind), hemophilia, or function disorder; or
  5. Hypersensitivity or known allergy to desmopressin.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Prophylactic intravenous tranexamic acid and prophylactic intravenous desmopressin.

    Within 20 minutes preceding anticipated skin incision, patients will receive preoperative prophylactic intravenous tranexamic acid at a dose of 1000 mg infused over 10 minutes for patients with estimated glomerular filtration rate (eGFR) \<25 ml/min/1.73m2 who do not receive dialysis before surgery and 500 mg infused over 10 minutes for patients who receive dialysis. Within 20 minutes preceding anticipated skin incision, patients allocated to the desmopressin intervention group will receive intravenous desmopressin at a dose of 20 mcg over 30 minutes.

    Drug: Desmopressin Injectable Solution · Drug: Tranexamic Acid Injectable Product

  • Experimental
    Prophylactic intravenous tranexamic acid and placebo.

    Within 20 minutes preceding anticipated skin incision, patients will receive preoperative prophylactic intravenous tranexamic acid at a dose of 1000 mg infused over 10 minutes for patients with eGFR \<25 ml/min/1.73m2 who do not receive dialysis before surgery and 500 mg infused over 10 minutes for patients who receive dialysis. Within 20 minutes preceding anticipated skin incision, patients allocated to the desmopressin control group will receive an intravenous infusion of 0.9% saline solution, administered over a duration of 30 minutes.

    Drug: Tranexamic Acid Injectable Product · Other: Placebo

  • Experimental
    Prophylactic intravenous desmopressin and placebo.

    Within 20 minutes preceding anticipated skin incision, patients will receive intravenous desmopressin at a dose of 20 mcg over 30 minutes. Patients will not receive prophylactic tranexamic acid. Within 20 minutes preceding anticipated skin incision, patients allocated to the tranexamic acid control group will receive an intravenous infusion of 0.9% saline solution. This saline solution will be administered over a duration of 10 minutes in a volume equivalent to that received by patients in the tranexamic acid intervention group.

    Drug: Desmopressin Injectable Solution · Other: Placebo

  • Placebo comparator
    Placebo and placebo.

    Within 20 minutes preceding anticipated skin incision, patients allocated to the tranexamic acid control group will receive an intravenous infusion of 0.9% saline solution. This saline solution will be administered over a duration of 10 minutes in a volume equivalent to that received by patients in the tranexamic acid intervention group. Within 20 minutes preceding anticipated skin incision, patients allocated to the desmopressin control group will receive an intravenous infusion of 0.9% saline solution, administered over a duration of 30 minutes.

    Other: Placebo

Interventions

  • DrugDeamino Arginine VasopressinStudies of Deamino Arginine VasopressinDeamino Arginine Vasopressin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous desmopressin, 20 mcg, single dose administration.

    Also known as: DDAVP

  • DrugTranexamic AcidStudies of Tranexamic AcidTranexamic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous tranexamic acid, 1000 mg single dose administration for patients with eGFR\<25 not yet receiving dialysis OR 500 mg single dose administration for patients receiving dialysis.

    Also known as: Cyklokapron

  • OtherPlacebo

    Intravenous 0.9% saline solution

06

What researchers measure

Primary outcomes

  1. Rate of recruitment

    A rate of 0.25 patients per study site per week

    Time frame: Through study completion, an average of 1.5 years

  2. Receipt of the allocated study drug within 1 hour before start of surgery for the tranexamic acid factorial

    Account of whether the patient began to receive study drug for the TXA factorial within an hour before skin incision. Target ≥80% of participants

    Time frame: Day of surgery

  3. Receipt of the allocated study drug within 1 hour before start of surgery for the desmopressin factorial

    Account of whether the patient began to receive study drug for the desmopressin factorial within an hour before skin incision. Target ≥80% of participants

    Time frame: Day of surgery

  4. Completion of 30-day follow-up

    Account of whether the patient or their next-of-kin could be contacted and completed the 30-day post-randomization assessment. Target ≥80% of participants

    Time frame: 30 days after randomization

Secondary outcomes

  1. Bleeding Independently Associated with Mortality after noncardiac Surgery (BIMS)

    Number of patients who experience BIMS

    Time frame: 30 days after randomization

  2. Bleeding Score

    10-category ordinal score. Minimum scores mean a better outcome. 0 denotes no bleeding or bleeding in which the nadir hemoglobin is ≥70 g/L, no red blood transfusion was given, no reoperation for reasons of bleeding occurred, and there was no death imminently or directly caused by bleeding. 1. denotes bleeding and post-operative hemoglobin \<70 g/L or 1 unit of blood (red blood cells or whole blood) transfused. 2. denotes bleeding and 2 units transfused. 3. denotes bleeding and 3 units transfused. 4. denotes bleeding and 4 units transfused 5. denotes bleeding and 5 units transfused. 6. denotes bleeding and 6 units transfused. 7. denotes bleeding and 7 units transfused. 8. denotes bleeding and 8 or more units of blood transfused. 9. denotes reoperation for reasons of bleeding. 10. denotes death imminently or directly caused by bleeding.

    Time frame: 30 days after randomization

  3. Reoperation for reasons of bleeding

    Number of patients who return to the operating room for surgical management of suspected documented bleeding

    Time frame: 30 days after randomization

  4. Blood (red blood cells or whole blood) transfused

    Number of units of blood transfused.

    Time frame: 30 days after randomization

  5. Blood (red blood cells or whole blood) transfused

    Number of units of blood transfused.

    Time frame: Up to and including postoperative day 3 after surgery

  6. Any blood transfusion (red blood cells or whole blood)

    Number of units of blood transfused.

    Time frame: 30 days after randomization

  7. Any blood transfusion (red blood cells or whole blood)

    Number of units of blood transfused.

    Time frame: Up to and including postoperative day 3

  8. Lowest measured hemoglobin concentration

    The mean absolute difference for continuous outcomes using linear regression with treatment allocation

    Time frame: 30 days after randomization

  9. Most recent hemoglobin concentration

    The mean absolute difference for continuous outcomes using linear regression with treatment allocation

    Time frame: 30 days after randomization

  10. Death

    Number of patients who die of any cause

    Time frame: 30 days after randomization

  11. Major arterial and venous thrombosis

    (i.e., composite of myocardial injury after noncardiac surgery \[MINS\], stroke, peripheral arterial thrombosis, dialysis vascular access thrombosis requiring anticoagulation or intervention, and symptomatic venous thromboembolism)

    Time frame: 30 days after randomization

  12. Myocardial Injury after Noncardiac Surgery (MINS)

    Number of patients who experience MINS

    Time frame: 30 days after randomization

  13. Myocardial Injury after Noncardiac Surgery (MINS) that meets criteria for myocardial infarction

    Number of patients who experience MINS that meets criteria for myocardial infarction (based on the Fourth Universal Definition of myocardial infarction)

    Time frame: 30 days after randomization

  14. MINS that is an isolated ischemic troponin elevation

    Number of patients who experience MINS that is an isolated ischemic troponin elevation

    Time frame: 30 days after randomization

  15. Stroke

    Number of patients experiencing a stroke

    Time frame: 30 days after randomization

  16. Non-hemorrhagic stroke

    Number of patients who experience a non-hemorrhagic stroke

    Time frame: 30 days after randomization

  17. Hemorrhagic stroke

    Number of patients who experience a hemorrhagic stroke

    Time frame: 30 days after randomization

  18. Peripheral arterial thrombosis

    Number of patients who experience a peripheral arterial thrombosis

    Time frame: 30 days after randomization

  19. Thrombosis of arteriovenous fistula or graft

    Number of patients who have thrombosis of arteriovenous fistula or graft

    Time frame: 30 days after randomization

  20. Symptomatic proximal venous thromboembolism

    Number of patients who experience symptomatic proximal venous thromboembolism

    Time frame: 30 days after randomization

  21. Symptomatic pulmonary embolism

    Number of patients who experience a symptomatic pulmonary embolism

    Time frame: 30 days after randomization

  22. Symptomatic proximal leg or arm deep venous thrombosis (DVT)

    Number of patients who experience a symptomatic proximal leg or arm DVT

    Time frame: 30 days after randomization

  23. Non-fatal cardiac arrest

    Number of patients who experience non-fatal cardiac arrest

    Time frame: 30 days after randomization

  24. Coronary revascularization procedure

    Number of patients who undergo coronary revascularization procedure

    Time frame: 30 days after randomization

  25. Clinically important atrial fibrillation or flutter

    Number of patients who experience clinically important atrial fibrillation or flutter

    Time frame: 30 days after randomization

  26. Acute heart failure or clinically important volume overload

    Number of patients who experience acute heart failure or clinically important volume overload.

    Time frame: 30 days after randomization

  27. Acute kidney injury (for patients not receiving dialysis before surgery)

    Number of patients who experience an acute kidney injury

    Time frame: 30 days after randomization

  28. New start of dialysis

    Number of patients who require new start of dialysis

    Time frame: 30 days after randomization

  29. Seizure

    Number of patients who experience a seizure

    Time frame: 30 days after randomization

  30. Clinically significant intraoperative hypotension

    Number of patients who experience clinically significant intraoperative hypotension

    Time frame: 30 days after randomization

  31. Clinically significant postoperative hypotension

    Number of patients who experience clinically significant postoperative hypotension

    Time frame: Up to and including the end of postoperative day 1

  32. Sepsis

    Number of patients who experience sepsis

    Time frame: 30 days after randomization

  33. Duration of surgery

    The time from skin incision to closure, in minutes.

    Time frame: 30 days after randomization

  34. Receipt of platelets

    Any transfusion of this blood product

    Time frame: 30 days after randomization

  35. Receipt of fibrinogen

    Any transfusion of this blood product

    Time frame: 30 days after randomization

  36. Receipt of fresh frozen plasma

    Any transfusion of this blood product

    Time frame: 30 days after randomization

  37. Receipt of cryoprecipitate

    Any transfusion of this blood product

    Time frame: 30 days after randomization

  38. Receipt of recombinant Factor VIIa

    Number of patients receiving recombinant factor VIIa

    Time frame: 30 days after randomization

  39. Receipt of prothrombin complex concentrate

    Number of patients who receive prothrombin complex concentrate

    Time frame: 30 days after randomization

  40. Prescribed erythropoiesis stimulating agent

    Number of patients receiving a weekly dose of erythropoiesis stimulating agent on prescription active at 30 days

    Time frame: 30 days after randomization

  41. Severe hyponatremia

    Measured serum sodium concentration \<125 meq/L

    Time frame: Up to and including the end of postoperative day 1

  42. Duration of hospital stay after surgery

    Cumulative number of nights spent in an acute care hospital

    Time frame: Day of surgery and ending the day of discharge

  43. Duration of critical care stay after surgery

    Cumulative number of nights spent in an intensive care unit

    Time frame: Day of surgery and ending the day of discharge

  44. Delayed graft function after kidney transplantation

    Receipt of dialysis

    Time frame: Within 7 days following kidney transplantation

  45. Persistent dialysis dependence

    Participant continues to receive dialysis after surgery.

    Time frame: 30 days after randomization

  46. Incisional site pain severity

    Rating of pain using the 10-point ordinal scale where 0 corresponds to no pain and 10 corresponds to the worst pain imaginable.

    Time frame: 30 days after randomization in the last 24 hours

07

Study locations

2 of 3 sites recruiting
  • London Health Sciences Centre
    London, Ontario N6A 5A5, Canada
    Recruiting
  • Centre Hospitalier de L'Universite de Montreal (CHUM)
    Montreal, Quebec H2X 0A9, Canada
    Active, not recruiting

    Not enrolling at this site.

  • McGill University University Health Centre
    Montreal, Quebec H3H 2R9, Canada
    Recruiting
    • Lin Jawhar · Contact
    • Shaifali Sandal, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Feb 2027, 20 months after the start.

Of 41 non-industry phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 69. This study's planned 20 months is below that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2024
First posted
Mar 29, 2024
StartActual
Jun 9, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Jun 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06337838
Responsible party
Sponsor
First posted
Mar 29, 2024
Start date
Jun 9, 2025
Primary completion
Feb 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 22, 2026

Study contacts

Ingrid Copland
Contact
brackets@phri.ca
905-296-5754
Pavel Roshanov, MC,MSc,FRCPC
principal investigator · Western University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Deamino Arginine Vasopressin · Tranexamic Acid

Start the discussion